当代成人Ross手术的长期结局:对当前临床实践的启示
本研究在单中心高容量中心连续纳入2011至2019年455例接受Ross手术的成人患者,前瞻性随访中位9.0年,评估手术安全性、长期生存、再干预、瓣膜血流动力学及自体移植根尺寸。结果显示手术死亡率0.4%,12年生存与年龄性别匹配的一般人群相当,自体移植再干预累积发生率1.1%±0.5%,肺动脉同种移植物再干预1.9%±0.9%,12年平均主动脉瓣跨瓣压差4.0±0.2 mm Hg,支持在有经验的中心对合适成人更广泛地考虑Ross手术。
要点
- 当代成人Ross手术手术死亡率0.4%,无患者-人工瓣膜不匹配,永久起搏器植入率0.8%。
- 12年自体移植再干预累积发生率1.1%±0.5%,术前主动脉瓣反流与狭窄者间无差异(P=0.39)。
- 12年生存与年龄性别匹配一般人群相当,平均主动脉瓣跨瓣压差4.0±0.2 mm Hg。
核心结论
- 在当代成人队列中,Ross手术与优异的长期生存、持久的瓣膜性能和低再干预率相关,包括术前主动脉瓣反流及年龄>50岁患者。
- 这些发现提供了重要的当代基准,支持在有经验的中心对适当选择的成人更广泛地考虑Ross手术。
研究设计与样本
- 单中心高容量三级中心前瞻性队列研究,2011至2019年连续纳入455例接受Ross手术的成人(平均年龄47±12岁,73%男性)。
- 所有患者接受系统性临床和超声心动图前瞻性随访,中位随访9.0年(Q1-Q3:7.3-11.1年),临床和超声随访完整率98%(4,191患者年,2,921次超声心动图)。
主要发现
- 手术死亡率0.4%(n=2),无患者-人工瓣膜不匹配,永久起搏器植入率0.8%(n=3)。
- 12年时实际生存与年龄和性别匹配的一般人群相当。
- 12年自体移植再干预累积发生率为1.1%±0.5%,术前主动脉瓣反流与狭窄患者间无差异(1.2%±1.2% vs 1.1%±0.6%;P=0.39)。
- 12年肺动脉同种移植物再干预累积发生率为1.9%±0.9%,任何心脏再干预为3.5%±1.0%。
- 12年时平均主动脉瓣跨瓣压差为4.0±0.2 mm Hg。
临床怎么用
- 在有经验的中心,对适当选择的成人(包括术前主动脉瓣反流及年龄>50岁者)可更广泛地考虑Ross手术。
- 当代Ross手术表现出优异的长期生存、持久的瓣膜血流动力学和低再干预率,可作为临床决策的基准参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With renewed enthusiasm for the Ross procedure in adults in recent years, long-term data using contemporary techniques are needed. OBJECTIVES: The purpose of this study was to evaluate long-term clinical and echocardiographic outcomes of the Ross procedure in a contemporary adult cohort. METHODS: From 2011 to 2019, 455 consecutive adults (mean age 47 ± 12 years; 73% male) underwent a Ross procedure at a single high-volume tertiary center. This includes our inaugural experience with the procedure. All patients were prospectively followed with systematic clinical and echocardiographic follow-up. Outcomes included operative safety, long-term survival, reinterventions, valve hemodynamics, and autograft root dimensions. Median follow-up was 9.0 years (Q1-Q3: 7.3-11.1 years), with 98% completeness of clinical and echocardiographic follow-up (4,191 patient-years and 2,921 echocardiograms). RESULTS: Operative mortality was 0.4% (n = 2). No patient-prosthesis mismatch occurred, and permanent pacemaker implantation was required in 0.8% (n = 3). At 12 years, actuarial survival was comparable to the age- and sex-matched general population. The cumulative incidence of autograft reintervention at 12 years was 1.1% ± 0.5%, with no difference between patients with preoperative aortic regurgitation and aortic stenosis (1.2% ± 1.2% vs 1.1% ± 0.6%; P = 0.39, respectively). The cumulative incidence of pulmonary homograft reintervention at 12 years was 1.9% ± 0.9%, and any cardiac reintervention was 3.5% ± 1.0% at 12 years. Mean aortic valve gradient at 12 years was 4.0 ± 0.2 mm Hg. CONCLUSIONS: In a large contemporary adult cohort with comprehensive follow-up, the Ross procedure was associated with excellent long-term survival, durable valve performance, and low reintervention rates, including in patients with preoperative aortic regurgitation and those >50 years of age. These findings provide an important contemporary benchmark and support broader consideration of the Ross procedure in appropriately selected adults in experienced centers.
引用
- El-Hamamsy I, Chauvette V, Bouhout I, et al. Contemporary Outcomes of the Ross Procedure in Adults: Implications for Current Clinical Practice. J Am Coll Cardiol. 2026. PMID: 42339796. doi:10.1016/j.jacc.2026.03.173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。